NCT00772577

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 386 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Aliskiren Hydrochlorothiazide	Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
DRUG	Ramipril	Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-10-15
• Last updated: 2011-03-11
• Results posted: 2011-03-02

Locations

6 sites across 1 country: United States